Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dolby Laboratories, Inc. (NYSE: DLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports, quarterly updates, proxy materials, and current reports on material events. As a Delaware corporation with Class A common stock listed on the New York Stock Exchange, Dolby files documents such as Form 10-K, Form 10-Q, Form 8-K, and the Definitive Proxy Statement (DEF 14A) with the U.S. Securities and Exchange Commission.
Dolby’s filings offer detailed insight into its licensing-focused business model, which centers on technologies like Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby OptiView, and related audio and imaging intellectual property. In its proxy statement and other filings, the company discusses its single reportable segment, the importance of royalty-based revenue, and the role of cinema hardware and premium cinema technologies in its overall revenue mix.
Through current reports on Form 8-K, Dolby discloses financial results, dividends, and executive compensation plans. These filings cover quarterly and annual revenue, net income, non-GAAP metrics, and capital return actions such as cash dividends on Class A and Class B common stock. They also describe executive bonus plans that tie incentive payouts to non-GAAP operating income, revenue, and other performance metrics.
The Definitive Proxy Statement (DEF 14A) provides information on corporate governance and executive compensation, including proposals for the election of directors, advisory votes on named executive officer compensation, and ratification of the independent registered public accounting firm. It also summarizes non-GAAP financial measures and includes reconciliations to GAAP in appendices.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, highlight key figures and themes, and make it easier to understand Dolby’s financial condition, risk disclosures, and governance practices. Investors can use this page to follow Dolby’s official communications to regulators, monitor dividend and capital allocation decisions, and review the frameworks used to evaluate and reward the company’s leadership.
Dolby Laboratories, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on February 3, 2026 via live webcast. Holders of Class A and Class B common stock, which carry one vote and ten votes per share respectively, voted together as a single class on all items.
All eight director nominees, including Kevin Yeaman, David Dolby, and others, were elected, each receiving over 384 million votes for, with broker non-votes of 3,884,937 on each director proposal. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 396,794,929 votes for and 2,216,964 against.
In addition, stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 25, 2026, with 400,209,219 votes for and 2,718,973 against. Overall, the meeting confirmed the existing board slate, executive pay program, and external auditor.
Dolby Laboratories director Simon Segars received an equity award of 3,908 restricted stock units of Class A common stock on 02/03/2026 under the company’s 2020 Stock Plan at a grant price of $0 per share. Each unit represents one share of Class A common stock upon vesting.
The units vest on the earlier of the first anniversary of the grant date or the day immediately before Dolby’s 2027 annual shareholders meeting, as long as Segars continues serving on the board. After this grant, he beneficially owns 47,150 Class A shares, including 3,908 unvested RSUs that remain subject to forfeiture until they vest.
Dolby Laboratories director and 10% owner David Dolby received an equity award of 3,908 restricted stock units (RSUs) of Class A common stock on February 3, 2026. The RSUs were granted at a price of $0 per unit under the company’s 2020 Stock Plan.
Each RSU represents a contingent right to receive one share of Class A common stock that will vest on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual stockholders’ meeting, as long as he continues to serve on the board. After this award, he beneficially owns 92,718 Class A shares, including the 3,908 unvested RSU shares that are subject to forfeiture until they vest.
Dolby Laboratories director Emily Rollins received an equity grant as part of her board compensation. On February 3, 2026, she was awarded 3,908 restricted stock units of Class A common stock at a price of $0 per share under Dolby’s 2020 Stock Plan.
Each unit represents one share that will vest on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual stockholder meeting, as long as she continues serving on the board. After this grant, she beneficially owns 13,541 Class A shares, including the unvested units, which remain subject to forfeiture until they vest.
Dolby Laboratories director Peter C. Gotcher received an equity award of 3,908 restricted stock units (RSUs) of Class A Common Stock on February 3, 2026. The RSUs were granted at a price of $0 under Dolby’s 2020 Stock Plan.
Each RSU represents a right to receive one share of Class A Common Stock upon vesting. Vesting occurs on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual meeting of stockholders, if Gotcher continues serving on the board.
After this grant, Gotcher beneficially owns 44,641 shares of Class A Common Stock, including 3,908 shares underlying unvested RSUs that are subject to forfeiture until they vest.
Dolby Laboratories director Anjali Sud reported a grant of 3,908 restricted stock units (RSUs) of Class A common stock on February 3, 2026 at a price of $0. The award was made under Dolby’s 2020 Stock Plan.
Each RSU represents a contingent right to receive one Dolby Class A share that vests on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual meeting of stockholders, if she continues serving on the board. After this grant, she beneficially owns 16,079 Class A shares, including 3,908 unvested RSU-based shares that remain subject to forfeiture until they vest.
Dolby Laboratories director Tony A. Prophet received an equity award in the form of restricted stock units. On 02/03/2026, he was granted 3,908 restricted stock units of Class A common stock at a price of $0 per unit under the company’s 2020 Stock Plan.
Each unit converts into one share of Class A common stock upon vesting. Vesting will occur on the earlier of the first anniversary of the grant date or the day immediately before Dolby’s 2027 annual stockholders’ meeting, if he continues serving on the board. After this grant, he beneficially owns 13,015 Class A shares, including the unvested units, which are subject to forfeiture until they vest.
Dolby Laboratories director Avadis Tevanian reported an equity award and updated share holdings. On February 3, 2026, he received 3,908 restricted stock units (RSUs) of Class A common stock at $0 under Dolby’s 2020 Stock Plan.
Each RSU represents one share of Class A common stock and will vest on the earlier of the first anniversary of the grant date or immediately before Dolby’s 2027 annual shareholders’ meeting, contingent on his continued board service. Following this grant, he beneficially owns 3,908 shares directly through these RSUs and 62,670 shares indirectly held by the Avadis Tevanian Jr. and Nancy Tevanian Trust.
Dolby Laboratories senior executive John D. Couling reported a sale of company stock. On February 2, 2026, he sold 6,667 shares of Dolby Class A common stock at $64.885 per share. After this transaction, he beneficially owned 123,041 shares in total.
This total includes 55,114 shares of Class A common stock underlying restricted stock units. These restricted stock units are subject to forfeiture until they vest, meaning Couling’s ability to keep those shares depends on future vesting conditions being met.
Dolby Laboratories insider John Couling has filed to sell additional common shares under Rule 144. The notice covers 6,667 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 02/02/2026, with an aggregate market value of 432,588.30. The filing notes 60,884,768 common shares outstanding and lists the NYSE as the trading venue.
The shares to be sold were originally acquired from the issuer as restricted stock and performance shares on various grant dates between 12/15/2020 and 12/15/2023. Over the past three months, Couling previously sold 7,273 common shares on 12/11/2025 for gross proceeds of 500,018.75 and 6,164 common shares on 11/20/2025 for gross proceeds of 407,563.68.